Effectiveness of Interferon Alpha-2b in Thalassemia Patients with Hepatitis C
Author Information
Author(s): Kalantari Hamid, Rad Neda
Primary Institution: Isfahan University of Medical Sciences
Hypothesis
Does the addition of ribavirin to interferon alpha-2b improve treatment outcomes for chronic hepatitis C in thalassemic patients?
Conclusion
Monotherapy with interferon alpha-2b is more effective than combination therapy with ribavirin for treating chronic hepatitis C in thalassemic patients.
Supporting Evidence
- 90.9% of patients in the monotherapy group achieved sustained viral response (SVR) compared to 44.4% in the combination therapy group.
- No significant differences were found in HCV RNA and AST levels between the treatment groups.
- The mean ALT level was significantly higher in the combination therapy group.
Takeaway
This study found that giving one medicine alone worked better than giving two medicines together for treating a liver infection in patients with a blood disorder.
Methodology
A randomized, double-blind, controlled trial with 32 thalassemic patients assigned to receive either interferon alpha-2b alone or in combination with ribavirin.
Limitations
The small sample size and lack of information on transfusion requirements.
Participant Demographics
Mean age 22 years, 59.4% male and 40.6% female.
Statistical Information
P-Value
0.049
Statistical Significance
p = 0.049
Want to read the original?
Access the complete publication on the publisher's website